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ABSTRACT 
Poor bioavailability is one of the most significant problems in the delivery of the ocular drug system. Ophthalmic ointments, solutions and 
suspensions are the most frequently used dosage forms to treat ocular disease, and their effectiveness as a drug are compromised by several 
limitations that lead to poor ocular bioavailability. In situ gel is one of the most promising strategy and solutions to improve the ocular 
bioavailability of drugs. The purpose of this review is to discuss the formulation and characterization of in situ gel. This review is written based on 
the data or information obtained by using several search engines and several scientific journals, focused on Poloxamer 407 and Hydroxy Propyl 
Methyl Cellulose (HPMC) bases combination. 
Active ingredients to treat ocular disease such as Ciprofloxacin, Fluconazole and Ofloxacin can be formulated with the combination of Poloxamer 
407 as polymer gelling agent and HPMC as viscosity enhancer to produce good quality in situ gel dosage forms. The in situ gel dosage forms can be a 
promising alternate solution for the ophthalmic delivery system. 
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INTRODUCTION 
Topical application of drugs is the most common route of 
administration for the treatment of many eye conditions. The eyes is 
special because of the structural and functional aspect of this organ 
makes it highly impervious to foreign substances and material. 
Protective mechanisms of the eye such as blinking, baseline and reflex 
lachrymation and drainage remove foreign ingredients including 
drugs from the eye’s surface. Because of it, targeting of drugs to eye 
tissues is one of the hardest challenge in drug delivery [1, 2]. 
Conventional and frequently used ophthalmic dosage forms such as 
solutions and suspensions have several drawbacks, for example-rapid 
precorneal elimination of drugs because of the nasolacrimal drainage, 
the need for frequent application and pulse release. Other dosage forms, 
which is ophthalmic ointments, provide prolonged contact with the eye 
surface. But it may trigger some side effects such as foreign body 
sensation, blurred vision and inconvenience to the patient [2, 3]. 
Physiological constraints imposed by the eye’s protective 
mechanism lead to low absorption of drugs and short duration of 
therapeutic effect. Drug absorption is also influenced by the 
chemical nature of the drugs, since the permeability of cornea 
depends on molecular size and hydrophobicity of drugs. In order to 
increase drug effectiveness, a dosage form that increases the contact 
time of the drug in the eye should be selected. This can lead into 
increased bioavailability, reduced systemic absorption and reduce 
the need for frequent drug administration, leading to the 
improvement of patient compliance. One of the solution to increase 
precorneal residence time is by increasing the viscosity of drug [4]. 
This condition can be achieved by gelling systems or in this case in 
situ gel dosage form [5]. The purpose of this journal review are to 
discuss the formulation and characterization of in situ gel drug made 
using a combination of poloxamer 407 and HPMC bases. 
Methods 
The source of data for this journal review about in situ gel 
formulation and characterization are summarized and cited from 
several international journals, obtained from the internet using 
internet browser software and search engine. 50 international 
journals are used as a reference, obtained from various sources. The 
keywords used include in situ gel, formulation, characterization, 
poloxamer, Hydroxy Propyl Methyl Cellulose/HPMC. 
DISCUSSION 
In situ gelling systems can be defined as viscous liquids, which 
undergo a phase transition from solution to gel when applied to the 
human body [1]. In situ-forming hydrogels can also be described as 
liquid form upon instillation and undergo phase transition in the 
ocular cul-de-sac to form a viscoelastic gel and this provides a 
response to environmental changes [5]. The triggers to phase 
change are either temperature, pH or ionic strength. 
In the temperature-based method, gelling of the solution is triggered by 
change in the temperature. Sustained drug delivery can be achieved by 
the use of a polymer that changes from solution to gel at the eyes 
temperature. But the disadvantage of this method is characterized by 
very high polymer concentration. The examples of temperature-based in 
situ gel is methylcellulose and smart hydrogels. In pH based method, 
gelling of the solution is triggered by a change in the pH. CAP latex cross 
linked polyacrylic acid and its derivatives such as carbomers are used. 
They are low viscosity polymeric dispersion in water, which undergoes 
spontaneous coagulation and gelation after instillation in the 
conjunctival cul-de-sac. In ionic strength-based method, of the solution, 
instilled is triggered by change in the ionic strength [6]. 
Gels that undergo sol-gel phase transition caused by a temperature 
change are called thermoresponsive in situ gels. Such gels have been 
extensively investigated as temperature-responsive materials for 
invertible thermoresponsive gelation under certain temperatures 
and concentrations [7]. 
The efficacy of ophthalmic hydrogels is mostly based on an increase 
of ocular residence time by enhancing the viscosity and 
mucoadhesive properties. Since resulted swollen hydrogel is 
aqueous-based, it is very comfortable in the patient's eye. Because of 
this, in situ gels are preferred since they are conveniently dropped in 
the eye as a solution, where undergo transition into a gel [8]. 
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One of the journals claims that among all in situ gel-forming systems, 
activation by change in ionic strength is most effective. The advantage is 
based on the fact that fluctuations in pH and temperature, which could 
cause changes in the gelation process, are not associated with the ion-
activated system. These fluctuations in pH could cause ocular irritation, 
and storage conditions could lead to changes in temperature [9]. 
There are several mechanisms of in situ gels based on its physical 
mechanism: swelling, diffusion and formation based on the chemical 
reaction. In the swelling mechanism, in situ formation may also 
occur when a material absorbs water from the surrounding 
environment and expand to the desired space. One such substance is 
myverol (glycerol mono-oleate), which is polar lipid that swells in 
water to form lyotropic liquid crystalline phase structures [10].  
In the diffusion mechanism, it involves the diffusion of solvent from 
polymer solution into surrounding tissue and results in precipitation 
or solidification of polymer matrix. N-methyl pyrrolidone (NMP) has 
been shown to be useful solvent for such system. And in the 
chemical reaction mechanism, chemical reactions that results in situ 
gelation may involve precipitation of inorganic solids from 
supersaturated ionic solutions, enzymatic processes, and photo-
initiated processes [11-13]. 
According to this journal written by Chand et al., The polymers used in in 
situ gel should be nontoxic and non-absorbable from the gastrointestinal 
tract. It should adhere quickly to moist tissue and should possess some 
site-specificity, be a non-irritant to the mucous membranes, and possess 
a wide margin of safety both locally and systemically. Another important 
thing, the cost of the polymer should be not too high so that prepared 
dosage form remains competitive [14]. 
Another journal written by Saini et al., describe the ideal 
characteristics of polymers for the preparation of in situ ophthalmic 
gel. It should be biocompatible, capable of adhering to mucus 
membrane, have pseudoplastic behavior, has good tolerance and 
optical clarity, influences the tear behavior and the polymer should be 
capable of decreasing the viscosity with increasing shear rate [15]. 
Laddha and Mahajan also describe three ideal properties for in situ 
formulations: physical state, phase transition and strength of gel 
[16]. First, the formulation should be a free-flowing liquid which 
allows ease of administration with reproducible dose delivery. 
Second, upon instillation, it should undergoes sol-to-gel formation 
by phase transition [17]. And the third, formed gel should be strong 
enough to withstand the shear force in the cul-de-sac, which 
prolongs the residence time of the drug [18]. 
Poloxamer and HPMC are two of the most widely used excipients in 
the formulation of in situ gel, mainly for the temperature-based type. 
Temperature-sensitive systems are the most commonly studied 
class of stimuli-responsive polymer systems for ocular targeting 
[19]. The use of a biomaterial that undermines the transition 
process from sol to gel form is triggered by a change in temperature 
is an attractive way to achieve in situ formation [20]. Physiologic 
temperature where there is no need of an external source of heat 
other than that of the body for gelation is the ideal phase transition 
temperature for this type of systems. Temperature-sensitive in situ 
gels can be classified into negatively thermosensitive, positively 
thermo-sensitive, and thermally reversible gels [21]. Poloxamer (or 
Pluronic) is the most commonly used polymers in preparations of 
thermosensitive in situ gel. Another widely used polymers are 
xyloglucan, chitosan and naturally occurring cellulose derivative. 
HPMC and MC belongs to the cellulose derivative group of the 
polymer [22]. Its also employed as another basic formulation 
component of in situ gel formulation. It functions as a viscosity 
enhancer in order to achieve the desired consistency so as to 
facilitate sustained drug release [23]. 
Poloxamer are a water-soluble tri-block copolymer that consisted of 
two polyethylene oxide and polypropylene oxide core in an ABA 
configuration. Poloxamer commercially, also known as pluronic and 
has good thermal setting property and increased drug residence time. 
It is used as a gelling agent and solubilizing agent. Poloxamer gives 
colorless, transparent gel. The mechanism of poloxamer is as follows: 
At room temperature (25 °C), it behaves as a viscous liquid and is 
transformed to transparent gel when temperature increases (37 °C). 
At low temperature, it forms a small micellar subunit in solution and 
increases in temperature results increase in viscosity, leads to swelling 
to form a large micellar cross-linked network [24, 25]. 
Poloxamers, commercially available and sold as Pluronic®, are triblock 
copolymers composed of polyethylene oxide (PEO) units and 
polypropylene oxide (PPO) units (PEO/PPO/PEO). It exhibits reverse 
thermal gelation under a certain temperature and concentration. 
Pluronic F68 (PF68), which is an analog of Pluronic F127 (PF127), was 
added to PF127 solution to increase its gelation temperature [26]. 
Poloxamer 407 (PF-127) is a nonionic surfactant composed of poly 
(ethylene oxide)-b(poly(propylene oxide)-b-poly(ethylene oxide) 
(PEO-PPOPEO) that shows amphiphilic behavior because of 
hydrophobic propylene oxide domains and hydrophilic ethylene 
oxide domains [27]. Pluronic F127 exhibits sol to gel transition at 37 
°C when used at a higher concentration of (25%-30%) (w/v). By 
using different series of poloxamers, cross-linking agents, by 
changing pH and ionic strength gelation, the temperature can be 
adjusted within the range of 33-36 °C [28]. 
HPMC is a semisynthetic, inert, viscoelastic polymer which is non-
ionic nontoxic, a good carrier for application of pharmaceutical drug 
which shows high swelling capacity [29, 30]. Methylcellulose 
solutions transform into opaque gel between 40-50 °C, whereas 
HPMC shows a phase transition between 75-90 °C. These phase 
transition temperatures can be lowered by chemical or physica 
modifications [31]. The mechanism of HPMC gellation process is as 
follows: Gelation of cellulose solutions is caused by the hydrophobic 
interactions between molecules containing methoxy substitution. At 
low temperatures, the macromolecules are hydrated and polymer-
polymer interaction is minimal. As the temperature is raised, the 
polymers will gradually lose their water of hydration. This condition 
is reflected by a decline in relative viscosity [32]. For the main 
discussion, we will compare three journals about Poloxamer 407 
and HPMC combination as reference. 
A. Controlled ocular drug delivery of ofloxacin using temperature 
modulated in situ gelling systems. Authors: Upendra Nagaich, Nidhi 
Jain, Divya Kumar and Neha Gulati. Published in Journal of the 
Scientific Society, Vol 40/Issue 2/May-August 2013 [32]. 
B. In situ Gelling Ophthalmic Formulations for Sustained Release and 
Enhanced Ocular Delivery of Fluconazole. Authors: Nabil Abdullah Ali 
Khatera, Osama A. Soliman and Elham A. Mohamed. Published in IOSR 
Journal of Pharmacy and Biological Sciences (IOSR-JPBS) Volume 11, 
Issue 2 Ver. I (Mar.-Apr.2016), PP 43-51 [33]. 
C. Ophthalmic In situ Sustained Gel of Ciprofloxacin, Preparation 
and Evaluation Study. Authors: Fadia Yassir Al-Bazzaz and Myasar 
Al-Kotaji. Published in International Journal of Applied 
Pharmaceutics Vol 10, Issue 4, 2018 [1].
 
Formulation 
Formulation of in situ gel from journal A 
Table 1: Formula of developed in situ gel systems 
Formulation FI F2 F3 F4 F5 
Ofloxacin (% w/v) 0.3 0.3 0.3 0.3 0.3 
Pluronic F 127 (% w/v) 16 18 20 22 24 
HPMC 50 cps (% w/v) 1.5 1.5 1.5 1.5 1.5 
NaCl (% w/v) 0.51 0.51 0.51 0.51 0.51 
Benzalkonium chloride (% w/v) 0.01 0.01 0.01 0.01 0.01 
Disodium hydrogen phosphate 1.125 1.125 1.125 1.125 1.125 
Distilled water (ml) 100 100 100 100 100 
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Formulation of in situ gel from journal B 
Table 2: Composition of fluconazole selected in situ gel formulations 
Ingredients Formulation code 
Temperature triggered in situ gelling system Ion activated in situ gelling system 
FI F2 F3 F4 
Fluconazole 0.3 0.3 0.3 0.3 
P407 15 15 - - 
HPMC 2 3 2 3 
ALG - - 0.4 0.3 
BKC 0.01 0.01 0.01 0.01 
Water q. s. 100 100 100 100 
 
Formulation of in situ gel from journal C 
Table 3: Composition of ophthalmic in situ gels of ciprofloxacin hydrochloride % (w/w) 
Formula Ciprofloxacin HC1 P407 HPMC Benzalkonium chloride Sodium chloride equivalent to 
F1 0.3 13 0.2 0.02 0.9 
F2 0.3 13 0.4 0.02 0.9 
F3 0.3 15 0.6 0.02 0.9 
F4 0.3 16.25 0.2 0.02 0.9 
F5 0.3 16.25 0.4 0.02 0.9 
F6 0.3 16.25 0.6 0.02 0.9 
F7 0.3 17.5 0.2 0.02 0.9 
F8 0.3 17.5 0.4 0.02 0.9 
F9 0.3 17.5 0.6 0.02 0.9 
Fl0 0.3 20 0.4 0.02 0.9 
F11 0.3 16.25 0 0.02 0.9 
F12 0.3 17.5 0 0.02 0.9 
 
The differences between all three formulations from each journal is 
the active ingredients used. Ofloxacin for the first, Fluconazole for the 
second and Ciprofloxacin for the third. Ofloxacin and Ciprofloxacin 
acts as an antibiotic, whereas Fluconazole on the other hand acts as an 
antifungal. The concentration of the excipients such as Poloxamer 407, 
HPMC, and Benzalkonium Chloride as preservative ingredients is 
different too. Another differences between the three of them is the 
amount of formulations variant. The third journals use 12 formula, 
higher than the other two journals (five and four formula for the first 
and the second journal). Because of this, the result from Journal C is 
better from Journal A and B. 
Preparation methods 
a. Journal A (Controlled ocular drug delivery of ofloxacin 
using temperature modulated in situ gelling system) 
Aqueous solutions of Pluronic F127 and HPMC were prepared by 
dispersing them in distilled water with constant stirring. Ofloxacin 
was dissolved in glacial acetic acid and added to HPMC solution. 
HPMC drug solution was then poured into Pluronic solution with 
constant agitation and was allowed to stand at 4 °C for 24 h to make 
a clear solution [32]. 
b. Journal B (In situ gelling ophthalmic formulations for 
sustained release and enhanced ocular delivery of fluconazole) 
Different in situ gelling preparations of FLZ (Fluconazole) were 
prepared under aseptic conditions to ensure the sterility of the final 
products. Based on the gelling capacity results, optimal 
concentration(s) of each polymer (P407, ALG, and CP934) with 
HPMC were determined. The required amount of each polymer was 
dispersed in 45 ml phosphate buffer saline (PBS) containing 0.01% 
benzalkonium chloride (BKC) as a preservative and stirred till 
complete dissolution. FLZ (0.3% w/v) was dissolved in 45 ml PBS 
and HPMC was added. The two resultant solutions were mixed using 
a magnetic stirrer. The volume was adjusted to 100 ml and 
transferred to a dry, clean, and sterile glass bottle. 
In situ gel of P407 was prepared by following the same method 
except that the polymer was added to previously cooled PBS to 4 °C. 
For plain formulations used for assessment of gelling capacity were 
prepared at the same method except that FLZ was not added [33]. 
c. Journal C (Ophthalmic in situ sustained gel of ciprofloxacin, 
preparation and evaluation study) 
Twelve different formulas of ciprofloxacin HCl in situ gel were 
prepared by using different concentrations of (P407) with different 
concentrations of HPMC. 
An in situ gel of ciprofloxacin was prepared by using the cold method 
[10, 34]. The required amount of (P407) was added to acetate buffer 
(pH 4.5) (at 4 °C) with gentle mixing and then allowed to hydrate 
overnight at the same temperature. The required amount of 
viscosity enhancing agent, HPMC, was dissolved in hot acetate buffer 
and cooled to 4 °C and then added to polymer solutions. 
Ciprofloxacin HCl was dissolved in the required amount of acetate 
buffer and then sodium chloride and benzalkonium chloride were 
added to the solution. After that, the drug solution was added to the 
polymer solution and mixed. 
The samples were then transferred to vials and stored in a 
refrigerator overnight. Finally, the vials were sterilized by autoclave 
at 121 °C at 15 psi for 20 min [1, 35]. 
The differences between the three preparation methods above is the 
sterilization process. Method from Journal B and C explains the 
aseptic and sterilization process to ensure that the product is in a 
sterile condition. 
Characterization 
Characterization and evaluation of in situ gel from the three journal 
is similar. 
a. Visual appearance and clarity 
The appearance of the prepared in situ gel systems was determined 
visually. Clarity of the in situ gel was observed against a white and 
black background for presence of any particulate matter [1, 36, 37]. 
b. Drug content 
In situ gel forming systems were also characterized for the drug content. 
1 ml of the preparation was left for 24 h in simulated artificial tear fluid 
(pH 7.4) and the sample was analyzed in ultraviolet spectrophotometer 
(UV 1601, Shimadzu, Japan) at 288 nm [1, 37, 38]. 
Kurniawansyah et al. 
Int J App Pharm, Vol 13, Issue 1, 2021, 27-31 
30 
c. Viscosity and pH 
The viscosity was measured using a Brookfield viscometer (LV-DVE 
model, Brookfield, USA). pH of the formulation was measured using 
a digital pH meter [1, 37-39]. 
d. Gelling capacity 
The gelling capacity was determined by placing one drop of the 
formulation in a vial containing 2 ml of freshly prepared artificial 
tear fluid and visually assessing time for gelation and the time taken 
for the gel to redissolve. The composition of artificial tear fluid used 
was NaCl 0.670 g, sodium bicarbonate 0.200 g, calcium chloride 
2H2
e. Ocular irritancy test 
O 0.008 g, in 100.0 ml of purified water [1, 40]. 
Draize irritancy test was performed on male albino rabbit (or female 
rabbit in Journal C) in order to demonstrate the safety potential of 
prepared formulation in animal model. A total of 100 µl of the 
optimized batch formula was placed in the lower cul-de-sac and was 
observed at various time intervals. Rabbits were visually examined 
for any redness, swelling or excessive tear production [1, 41]. 
f. In vitro studies 
Dissolution studies of samples were performed using Franz diffusion 
apparatus and phosphate buffer (pH 7.4) as a dissolution medium. 
Phosphate buffer with pH 7.4 will simulate the lachrymal fluid. The 
temperature was maintained at 37+0.5 °C with the speed of rotation 
maintained at 100 rpm. The samples were withdrawn at various 
time intervals and analysed spectrophotometrically for the drug 
content [1, 42-46]. 
g. In vivo studies 
In vivo therapeutic efficacy of developed optimized formulation and 
marketed eye drop formulation was investigated by using 
normotensive New Zeland albino rabbits. Intra ocular pressure of 
normotensive rabbits decreased within 1 h administration of single 
dose of developed in situ gel system and showed 10.86±4.33 % 
reduction which continued upto 8 h with 31.22±3.65 % reduction 
(p<0.01). It is worthy to note that marketed eye drop formulation 
immediately reduced intraocular pressure with 18.22±4.42 % up to 
2 to 3 h. From the in vivo study, it was concluded that the after 
administration of developed in situ gel in the rabbit eye, it turned 
out in gel form. During gel formulation, formulation got converted 
into the gel and thus drug release become slowly. Developed 
formulation confirmed gelling ability of poloxamer-407 at 
physiological conditions where as HPMC K15M enhances viscosity 
and sustained release profile of developed formulation. It was also 
observed that initial reduction in intraocular pressure was very 
rapid, this may be due to slow conversion of solution to gel 
formulation, but the reduction in intraocular pressure became slow 
in latter period after gel formation. It was observed after 
administration of marketed eye drop formulation, the rapid 
reduction in intraocular pressure upto 3 h, but due to liquid nature 
of formulation it had no ability to retain in cul de sac region. The 
results showed that after 3 h % decrease in IOP again decrease in 
case of marketed formulation due to its liquid nature [47, 48-50]. 
Evaluation result from all three journals and formulations shows 
that the developed formulation of in situ gel using combination of 
Poloxamer 407 (Pluronic F127) as gelling agent and HPMC as 
viscosity modifying agent is succesfully formulated. The optimized 
formula from each of the three journals represent a promising 
alternative solution to the conventional ophthalmic dosage forms 
because of its ability to enhance bioavailability. 
CONCLUSION 
Ophthalmic in situ gel is able to change into gel when applied to the 
eye. An in situ gel drug delivery system provides several benefits, such 
as prolonged pharmacological duration of action, simpler production 
techniques, and low cost of manufacturing as compared to 
conventional drug delivery systems. Poloxamer 407 is a well-known 
stimuli-responsive polymer type with thermoresponsive behaviour. It 
is commonly used as an eye drug delivery system as it could prolong 
drug release for eye tissue. The addition of hydroxypropyl methyl 
cellulose (HPMC) can reduce the concentration of poloxamer 407 
needed to form in situ gel gelation. Active ingredients to treat ocular 
disease such as Ciprofloxacin, Fluconazole and Ofloxacin can be 
formulated with the combination of Poloxamer 407 as polymer gelling 
agent and HPMC as viscosity enhancer to produce a good quality in situ 
gel dosage forms. Compared to the conventional ophthalmic dosage, 
the in situ gel dosage forms can be a promising alternate solution for 
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